Cargando…

Systems Signatures Reveal Unique Remission-path of Type 2 Diabetes Following Roux-en-Y Gastric Bypass Surgery

Roux-en-Y Gastric bypass surgery (RYGB) is emerging as a powerful tool for treatment of obesity and may also cause remission of type 2 diabetes. However, the molecular mechanism of RYGB leading to diabetes remission independent of weight loss remains elusive. In this study, we profiled plasma metabo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Qing-Run, Wang, Zi-Ming, Wewer Albrechtsen, Nicolai J., Wang, Dan-Dan, Su, Zhi-Duan, Gao, Xian-Fu, Wu, Qing-Qing, Zhang, Hui-Ping, Zhu, Li, Li, Rong-Xia, Jacobsen, SivHesse, Jørgensen, Nils Bruun, Dirksen, Carsten, Bojsen-Møller, Kirstine N., Petersen, Jacob S., Madsbad, Sten, Clausen, Trine R., Diderichsen, Børge, Chen, Luo-Nan, Holst, Jens J., Zeng, Rong, Wu, Jia-Rui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835566/ https://www.ncbi.nlm.nih.gov/pubmed/29422288 http://dx.doi.org/10.1016/j.ebiom.2018.01.018

Ejemplares similares

Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass
por: Jonsson, Isabella, et al.
Publicado: (2021)

Exaggerated Glucagon-Like Peptide 1 Response Is Important for Improved β-Cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes
por: Jørgensen, Nils B., et al.
Publicado: (2013)

Chenodeoxycholic acid stimulates glucagon‐like peptide‐1 secretion in patients after Roux‐en‐Y gastric bypass
por: Nielsen, Signe, et al.
Publicado: (2017)

Sustained Improvements in Glucose Metabolism Late After Roux-En-Y Gastric Bypass Surgery in Patients with and Without Preoperative Diabetes
por: Jørgensen, Nils B., et al.
Publicado: (2019)

Secretin release after Roux-en-Y gastric bypass reveals a population of glucose-sensitive S cells in distal small intestine
por: Modvig, Ida M., et al.
Publicado: (2020)

Roux-en-Y gastric bypass surgery of morbidly obese patients induces swift and persistent changes of the individual gut microbiota
por: Palleja, Albert, et al.
Publicado: (2016)

Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss()
por: Holst, Jens Juul, et al.
Publicado: (2018)

Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy
por: Hedbäck, Nora, et al.
Publicado: (2022)

Macrophage activation marker sCD163 is associated with liver injury and hepatic insulin resistance in obese patients before and after Roux‐en‐Y gastric bypass
por: Kazankov, Konstantin, et al.
Publicado: (2022)

Primary weight loss failure after Roux-en-Y gastric bypass is characterized by impaired gut-hormone mediated regulation of food intake
por: Bojsen-Møller, Kirstine Nyvold, et al.
Publicado: (2023)

Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies
por: Pedersen, Julie Steen, et al.
Publicado: (2021)

Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2022)

Methods and Guidelines for Measurement of Glucagon in Plasma
por: Holst, Jens J., et al.
Publicado: (2019)

Roles of increased glycaemic variability, GLP-1 and glucagon in hypoglycaemia after Roux-en-Y gastric bypass
por: Tharakan, George, et al.
Publicado: (2017)

SAT032 Circulating Neprilysin Activity Is Increased In Type 2 Diabetes And Fatty Liver Disease, And Reduces Following Bariatric Surgery And Liraglutide Therapy
por: Sampson Kjeldsen, Sasha Alexandra, et al.
Publicado: (2023)

The intestinal distribution pattern of appetite- and glucose regulatory peptides in mice, rats and pigs
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

Proteomics reveals the effects of sustained weight loss on the human plasma proteome
por: Geyer, Philipp E, et al.
Publicado: (2016)

Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy
por: Kjeldsen, Sasha A.S., et al.
Publicado: (2023)

Glucagon‐like peptide‐1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP‐1 receptors
por: Ronn, Jonas, et al.
Publicado: (2017)

Glucagon Receptor Signaling and Lipid Metabolism
por: Galsgaard, Katrine D., et al.
Publicado: (2019)

Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2017)

Nonalcoholic Fatty Liver Disease Impairs the Liver–Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis
por: Pedersen, Julie Steen, et al.
Publicado: (2020)

On the relationship between glucose absorption and glucose‐stimulated secretion of GLP‐1, neurotensin, and PYY from different intestinal segments in the rat
por: Kuhre, Rune E., et al.
Publicado: (2017)

Health care professionals from developing countries report educational benefits after an online diabetes course
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2017)

Identification of ADAM12 as a Novel Basigin Sheddase
por: Albrechtsen, Reidar, et al.
Publicado: (2019)

Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB
por: Engelbrechtsen, L., et al.
Publicado: (2017)

Effects of Roux-en-Y gastric bypass on fasting and postprandial inflammation-related parameters in obese subjects with normal glucose tolerance and in obese subjects with type 2 diabetes
por: Lindegaard, Kirsten Katrine, et al.
Publicado: (2015)

Effects of Roux-en-Y Gastric Bypass on Fasting and Postprandial Levels of the Inflammatory Markers YKL-40 and MCP-1 in Patients with Type 2 Diabetes and Glucose Tolerant Subjects
por: Thomsen, Stine Brinkløv, et al.
Publicado: (2013)

The Role of the Transsulfuration Pathway in Non-Alcoholic Fatty Liver Disease
por: Werge, Mikkel Parsberg, et al.
Publicado: (2021)

GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass
por: Guimarães, Marta, et al.
Publicado: (2015)

Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers
por: Tan, Tricia, et al.
Publicado: (2017)

Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes
por: Kjeldsen, Sasha A S, et al.
Publicado: (2023)

A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats
por: Hoelmkjaer, Kirsten M., et al.
Publicado: (2016)

Individuals with type 2 diabetes have higher density of small intestinal neurotensin-expressing cells
por: Ferreira, Filipa P., et al.
Publicado: (2023)

A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia
por: Lobato, Carolina B., et al.
Publicado: (2020)

Glucagon Receptor Signaling and Glucagon Resistance
por: Janah, Lina, et al.
Publicado: (2019)

Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans
por: Modrzynska, Justyna, et al.
Publicado: (2021)

Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides
por: Challis, Benjamin G, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_uvuh6uk18q4ckhjiob5haoct72